Retatrutide, Eli Lilly's triple agonist weight-loss drug, nears the end of phase 3
Doctors say early safety looks similar to other GLP-1s, with weight loss around 28 percent over two years, and warn against gray-market versions.
Recap by typeshit. Full story at Women's Health.